Renal impairment (RI) significantly impacts the clearance of drugs through changes in the glomerular filtration rate, protein binding and alterations in the expression of renal drug transport proteins and hepatic metabolizing enzymes. The objectives of this study were to evaluate quantitatively the effects of renal impairment on the pharmacokinetics of drugs undergoing renal transporter-mediated reabsorption. A previously published semi-mechanistic kidney model incorporating physiologically relevant fluid reabsorption and transporter-mediated active renal reabsorption (PMID: 26341876) was utilized in this study. The probe drug/transporter pair utilized was γ-hydroxybutyric acid (GHB) and monocarboxylate transporter 1 (SCL16A1, MCT1). γ-Hydroxybutyric acid concentrations in the blood and amount excreted into urine were simulated using ADAPT 5 for the i.v. dose range of 200-1500 mg/kg in rats and the impact of renal impairment on CL R and AUC was evaluated. A 90% decrease in GFR resulted in a > 100-fold decrease in GHB CL R . When expression of reabsorptive transporters was decreased and f u was increased, CL R approached GFR. The effect of renal impairment on CL R was reduced when the expression of drug metabolizing enzymes (DME) was increased as a result of increased metabolic clearance; the converse held true when the DME expression was decreased. In conclusion, this study quantitatively demonstrated that the effects of renal insufficiency on the clearance of drugs is modulated by transporter expression, contribution of renal clearance to overall clearance, expression of drug metabolizing enzymes, fraction unbound and drug-drug interactions with inhibitors of renal transporters that may be increased in the presence of renal impairment.
| INTRODUCTION
Renal impairment (RI) is a major health concern both in the USA and globally. The prevalence of chronic kidney disease (CKD) is 10%, and was ranked as 18th in the list of causes of the total number of deaths worldwide (Chronic Kidney Disease, 2014) . In the USA, the prevalence of chronic kidney disease is greater than 13%, affecting over 25 million adults (Nolin, Naud, Leblond, & Pichette, 2008) . Renal impairment is implicated in many disease states including nephritis, glomerulonephritis, type-II diabetes and auto-immune diseases such as lupus erythematosus (Chronic Kidney Disease, 2014) . One of the earliest reports of the impact of renal impairment on the pharmacokinetics (PK) of drugs was published by Dr Gerhard Levy, who described the three key principles: (1) the quantitative contribution of each route of elimination is proportional to the clearance value of that route relative to body clearance; (2) the reduction in the glomerular filtration rate (GFR) caused by renal impairment is, as a first approximation, an indication of the reduction in a drug's CL R ; and (3) since severe renal impairment causes a reduction in the plasma protein binding of many drugs, the metabolic clearance of many extensively metabolized drugs will be increased (Levy, 1977) . The characterization of the effects of renal impairment on PK is of vital importance to provide predictions for proper dosing of medications involved in renal impairment, and with the disease states associated with renal impairment (Lam, Banerji, Hatfield, & Talbert, 1997; Verbeeck & Musuamba, 2009 ). Renal impairment has been shown to affect the expression and activity of both drug transporters (DTs) and drug metabolizing enzymes (DMEs) (Sun, Frassetto, & Benet, 2006) .
In rats, experimentally induced renal impairment resulted in lower amounts of organic anion transporter 1 and 3 (Oat1 and Oat3), as well as organic cation transporter 2 (Oct2) protein in the kidney, compared with controls, while the protein expression of ABC transporters (P-glycoprotein, Mrp2 and Bcrp) was largely unchanged, or increased for Mrp2 (Komazawa et al., 2013; Sun et al., 2006) . Naud et al. (2011) also reported the increased protein expression of Mrp2 with renal impairment, and also the increased expression of Mrp4 and Oatp2 in rat kidneys isolated from animals with a 5/6 nephrectomy (Naud et al., 2011) . The activity of these transporters was also shown to be inhibited by uremic toxins and endothelin-1, compounds that are associated with renal impairment (Sun et al., 2006) . Importantly, Brandoni and Torres (2015) reported that in in vivo experimental models of acute kidney failure, that there was a negative correlation between uremia and the renal protein expression of Oat1 and Oat3 (Brandoni & Torres, 2015) .
Numerous drug metabolizing enzymes have also been shown to be affected by renal impairment (Brandoni & Torres, 2015) . In experimental models of end stage renal disease (ESRD), decreases in protein expression and activity of Cyp1a1, Cyp2c11, Cyp3a1, Cyp3a2, Nat1 and Nat2 were observed (Nolin et al., 2008) . These changes in expression and activity have been shown to have an impact on the clinical pharmacokinetics (PK) of several drugs in patients with chronic kidney disease including lidocaine, cerivastatin, cyclophosphamide, roxithromycin and others. Renal impairment has also been implicated in the alteration of protein binding for drugs such as phenytoin, warfarin and morphine (Nolin et al., 2008) .
Currently, the FDA recommends clinical PK studies to investigate the effect of renal impairment on the PK of new drugs (CDER, 2010) . A simulation-based approach utilizing a semi-mechanistic model will enable potential prediction of the effects of renal impairment on PK using data that have already been collected, prior to clinical studies. For these simulations a previously developed PK model for γ-hydroxybutyric acid was used that includes a semi-mechanistic kidney model incorporating physiologically relevant fractional fluid reabsorption from various nephron segments, that incorporated monocarboxylate transporter/sodiumdependent monocarboxylate transporter 1 (MCT1/SMCT1)-mediated renal reabsorption of γ-hydroxybutyric acid and L-lactate, with physiologically based disposition (Dave & Morris, 2015) .
We hypothesize that our previously qualified mechanistic and physiologically based PK model can be used to provide insight, through the use of simulations, on drug disposition by utilizing knowledge of drug transport and metabolism kinetic parameters, changes in the expression of drug transporters and drug metabolizing enzymes, and physiological changes that occur with renal impairment or chronic kidney disease.
The overall objective is to evaluate qualitatively the effects of renal impairment on the renal and total clearance of a drug with transportermediated renal drug reabsorption and saturable metabolism. Using γ-hydroxybutyric acid as a model substrate to illustrate the effects of renal impairment on CL R and CL, simulations examined the effect of changes in glomerular filtration rate, kidney transporter expression, drug metabolizing enzyme expression, protein binding and renal DDI, which may be mediated by higher concentrations of uremic toxins or other endogenous compounds present with renal impairment.
| MATERIALS AND METHODS

| Pharmacokinetic model
In this study, the probe drug/transporter pair utilized was γ-hydroxybutyric acid and MCT1. γ-Hydroxybutyric acid is a naturally occurring short-chain fatty acid and displays non-linear pharmacokinetics in rats (Lettieri & Fung, 1979) and humans (Palatini et al., 1993; Scharf, Lai, Branigan, Stover, & Berkowitz, 1988) , including capacity-limited absorption (Arena & Fung, 1980; Palatini et al., 1993) , capacity-limited metabolism in the liver (Palatini et al., 1993) , and capacity-limited renal vectorial reabsorption mediated by SMCT1 (SLC5A8, brush-border membrane) and MCT1 (SLC16A1, basolateral membrane) (Morris, Hu, & Wang, 2005) . We utilized a previously established semi-mechanistic kidney model incorporating physiologically relevant fluid reabsorption (67% from proximal tubules (S1-S3), 15% from loop-of-Henle, 16% from distal tubules and collecting ducts) and transporter-mediated active renal reabsorption (Dave & Morris, 2015) . The three key model components include (1) a semimechanistic kidney component incorporating physiologically relevant fluid reabsorption and transporter-mediated active reabsorption and γ-hydroxybutyric acid-specific components incorporating (2) non-linear renal transport kinetics (MCT1/SMCT1) and (3) systemic saturable metabolism and distribution of GHB as illustrated in Figure 1 . The kidney model assumes that about 67% of the total filtrate is reabsorbed from the proximal tubule (Khurana, 2014; Lash, 2007; Lote, 2000) .
The proximal tubule lumen segment was subdivided into four lumen segments, which yielded three S1 segments (S1-1, S1-2 and S1-3) and a S2 + S3 segment. About 2/3 of the total fluid reabsorption from proximal tubules occurs from the S1 segment (Lash, 2007) therefore, subdividing the S1 segment allows for incorporating the gradual process of fluid reabsorption across the proximal tubule. This also accounts for changes in drug concentration as a result of the decrease in the filtrate volume and the concentration of drug available for transport in subsequent segments. The fraction of fluid reabsorption from each of the three subsections of S1 is considered to be equal in magnitude. Figure 1 and Table 1 detail the fractional decrease in flows and volumes of the filtrate, relative to GFR, with sequential fluid reabsorption. A list of all model parameters is provided in Table 1 . The model equations are described in brief below and in detail in Dave and Morris (2015) .
| Blood compartment
The blood compartment (Equation (1)) is the depot for γ-hydroxybutyric acid (GHB) input. Previous data in our laboratory have investigated the blood to plasma (B/P) partitioning of GHB over a wide dose-range of 400-1500 mg/kg i.v. dose. The highest GHB dose assessed in the present manuscript was also 1500 mg/kg i.v.. The B/P partitioning of GHB was 0.75 and it did not exhibit any capacity limitation over this dose range (Morse, Felmlee, & Morris, 2012) . From the blood (BL), GHB distribution to the liver (LI), the kidneys (KI) and the remainder of the body (RM) as described as:
| Liver and remainder compartments
Equations (2) and (3) describe the distribution of γ-hydroxybutyric acid into the liver and the remainder compartments, respectively, with the initial condition (IC) set to 0. The saturable metabolism of GHB was incorporated as a single Michaelis-Menten equation.
2.4 | Compartments incorporating physiologically relevant fluid reabsorption and transporter-mediated renal reabsorption
The blood flow to the kidneys (Q KI ) carries γ-hydroxybutyric acid to the glomerulus (GLM), where a fraction of Q KI becomes the GFR and the remaining fraction drains into the peritubular capillaries as:
The fluid reabsorption from the three S1 segments of proximal tubules (PT), which is 2/3 of the total fluid reabsorption from PT is described as:
The remaining 1/3 of the total fluid reabsorption from proximal tubules occurs from the S2 and S3 segments (S2 + S3) as described in Equation (8), where LOH is the Loop of Henle.
The MCT1/SMCT1-mediated reabsorption of γ-hydroxybutyric acid from the brush border membrane (BBM) into the PT cells and MCT1-mediated transport from the basolateral membrane (BLM) into the renal blood (RBL) is described in Equations (8) and (9).
FIGURE 1 A semi-mechanistic and physiologically relevant pharmacokinetic model for γ-hydroxybutyric acid. Symbols and their description are provided in Table 1 . The model is adapted from Dave and Morris (2015) dA PTC dt ¼
The term Q KI -Q U accounts for the flow balance in the system: about 98% of fluid is reabsorbed every minute, where urine flow (Q U ) is~1-2% of GFR (Khurana, 2014; Lash, 2007; Lote, 2000) . As V S1_1 (ml), Q S1_1 (ml/min) Volume and flow of filtrate in lumen of 1st sub-segment of S1 segment of proximal tubule GFR V S1_2 (ml), Q S1_2 (ml/min) Volume and flow of filtrate in lumen of 2nd sub-segment of S1 segment of proximal tubule
V S1_3 (ml), Q S1_3 (ml/min) Volume and flow of filtrate in lumen of 3rd sub-segment of S1 segment of proximal tubule [C] Jonin and Bonjour, 1985.
[D] Khurana, 2014; Lash, 2007; Lote, 2000 .
[E] Morris et al., 2005; Wang, Wang, & Morris, 2008. [F] Wang et al., 2006.
[G] Dave & Morris, 2015. dA
The model outputs for the two PK endpoints, blood concentrations (C BL ) and cumulative amount excreted unchanged into urine (A e ) of γ-hydroxybutyric acid are:
2.5 | Simulation study design γ-Hydroxybutyric acid concentrations in the blood and amount excreted into urine were simulated for the i.v. dose range of 200-1500 mg/kg in rats using the model, simulations were performed assuming a 300 g rat. All simulations were performed using SIM algo- Wang, 2009 ). Renal impairment was incorporated into the model by modulating the GFR parameter and perturbing its value from 2.2 ml/ min (100% renal function) to 0.22 ml/min (10% renal function). Modulation of renal function was confined to decreasing GFR as the decrease in GFR is the major contributor to CL R for γ-hydroxybutyric acid; other physiological characteristics of the kidney were held constant. To study MCT1-mediated DDI, non-competitive and competitive inhibition of MCT1 was included in the model, using Equations (17) and (18), respectively, where R is the ratio of concentration of an inhibitor administered at steady-state ([I]) and the inhibition constant (K i ):
To evaluate the effects of renal impairment on dose-dependent PK of GHB, simulations were performed varying GFR from 10% to FIGURE 2 Model simulations for γ-hydroxybutyric acid concentrations in blood (a-c) and cumulative amount excreted unchanged into urine (A e ) (d-f), when renal function is altered (100%-10%): (a,d) 200 mg/kg, (b,e) 600 mg/kg, and (c,f) 1500 mg/kg doses of γ-hydroxybutyric acid 100% for doses of 200, 600 and 1000 mg/kg. To evaluate the effects of renal function on CL R of GHB (1500 mg/kg dose), when the expression of MCT1/SMCT1 is altered, the V MAX, BBM and V MAX, BLM parameters were altered ±2-and ± 5-fold for 100%, 50% and 10% GFR. The effects of DDI, examining non-competitive and competitive inhibition of GHB renal reabsorption, were also investigated along with the same alterations in MCT1/SMCT1 expression utilizing the parameter R (1, 10 and 100). The impact of protein binding (f u × GFR) was investigated with the same alterations in MCT1/SMCT1 expression. Protein binding was altered by changing f u from 0.1 to 1.0 (It should be noted that GHB is not protein bound, so these simulations are not relevant for GHB itself, but would be for other compounds undergoing active reabsorption.). Finally, the impact of altering the expression of drug metabolizing enzymes was included by perturbing V MAX, MET ± 1.5, ± 2 and ± 5 fold with GFR 100%, 50% and 10%.
The AUC 0-∞ were obtained using the NCA feature in PKSolver add-on package in MS Excel. CL R was calculated as the ratio of amount of γ-hydroxybutyric acid excreted unchanged into urine at time infinity (A e, ∞ ) and AUC 0-∞ .
3 | RESULTS
| Effects of RI on the dose-dependent PK of GHB
Renal impairment led to increased blood concentrations of γ- demonstrate that as renal function (GFR) was reduced, exposure to GHB increased for each dose tested. This effect was dose-dependent, with the greatest increase in AUC seen with the 1000 mg/kg dose ( Figure 2c ). The decrease in A e∞ and CL R was also dose dependent, with the greatest reduction in A e∞ and the smallest reduction in CL R seen for the 200 mg/kg dose relative to 100% GFR (Figure 2d ). When GFR was reduced from 100% to 10%, there was a reduction in A e∞ of over 55-fold for all doses (Table 2) . For all doses, CL R was reduced to a similar value of 4.3 μl/min when GFR was reduced from 100% to 10%.
The fold reduction in CL R for this change in GFR was over 100-fold for all doses and increased with increasing doses (Table S2) . Overall CL was reduced the least for the 200 mg/kg dose (1.3-fold compared with 2-and 3.2-fold 600 and 1000 mg/kg doses) ( Table 2 ). Figure 3 shows the direct relationship between the loss of renal function and decreasing CL R for GHB across all doses tested.
3.2 | Effects of renal function with altered transporter expression, transporter inhibition and protein binding on the CL R and CL of GHB In these simulations, one dose (1500 mg/kg) was used. When the expression of reabsorptive transporters was decreased, there was an accompanying increase in CL R (Figure 4a ). This led to an increase in CL, although this increase was not as pronounced as the increase in CL R (Table 2 and Figure 4b ). When drug transporter (DT) expression was increased, CL R and CL were decreased, but again the effect was less for CL than for CL R (Figure 4 ). The CL R decreased when GFR was reduced even with maximal inhibition of transport, indicating that CL R was still dependent on renal function. When the expression of reabsorptive transporters was increased (Figure 5b,c) , a greater degree of inhibition (higher value of R) was needed to achieve maximal CL R . Conversely, when the expression was decreased (Figure 5d ,e), maximal CL R was achieved with lower values of R.
The same trends were observed for competitive inhibition (data not shown). The effect of competitive inhibition was not as great as that of non-competitive inhibition. Under the same conditions, CL R values ranged from 0.01-to 3.55-fold higher for non-competitive inhibition compared with competitive inhibition (Table 3 and S1). In general, the differences in CL R for non-competitive and competitive inhibition were less than-2 fold. However, there were a few incidences when the difference between CL R for non-competitive and competitive inhibition was greater than 2-fold: this generally occurred when GFR was reduced to 10% (Table S2) . This is likely due to the fact that the low GFR resulted in low tubular concentrations of γ-hydroxybutyric acid, where inhibition of K m would be more important than decreases in the capacity for reabsorption. and minimized with an increased expression (Figure 6b,c) . For all degrees of DT expression, maximal CL R was achieved when renal function and fraction unbound were also maximal. There was also an increase in CL when f u was increased for all levels of expression (Table 4) . As with CL R , this effect was maximized with a lower expression of reabsorptive transporters, and minimized with a higher expression (Table 4) . For all levels of DT expression, when f u was reduced to 0.1, CL was 0.39 ± 0.038 ml/min.
3.3 | Effects of renal function and altered DME expression on the CL R and CL of GHB
The alteration of liver drug metabolizing enzyme expression had a limited effect on γ-hydroxybutyric acid CL R . When DME expression was increased 5-fold, there was a 13% increase in CL R ; similarly, when DME expression was decreased 5-fold there was a 15% reduction in CL R (Figure 7 , Table 5 ). When renal function was decreased by 50%, the magnitude of change in CL R increased to approximately 20% for both an increase and decrease in DME expression. However, when GFR was decreased to 10%, the changes in CL R were less than 1%
for all changes in DME expression ( Figure 7 , Table 5 ).
The effects of drug metabolizing enzyme expression on CL were more pronounced. When the expression of DMEs was increased 5-fold, there was a 105% increase in CL. When the expression of DMEs was decreased 5-fold, there was a 40% decrease in CL. Unlike CL R , when GFR was decreased the effects of DME expression changes were magnified. When GFR was reduced to 10%, increasing DME expression (5)-fold increased CL 380%, while decreasing expression (5)-fold decreased CL by 80% (Table 5 ). When DME expression was decreased, the fraction excreted (f e ) was increased, conversely, when DME expression was increased, f e decreased (Table 5 ). This effect was greatest when GFR was minimal (Table 5) . 
| DISCUSSION
Renal impairment is a major global health concern and the impact of this disease has been shown to impact the PK of xenobiotics. In addition to reducing GFR, renal impairment has been shown to affect the expression of renal, hepatic and intestinal DTs and drug metabolizing enzymes in experimental models (Dreisbach & Lertora, 2008; Naud et al., 2011; Nolin et al., 2008) . Drug plasma protein binding has also been shown to be altered in RI due to uremia, hypoalbuminemia and drug interactions with uremic toxins (Keller, Maiga, Neumayer, Lode, & Distler, 1984; Vanholder, Van Landschoot, De Smet, Schoots, & Ringoir, 1988 (Katsube et al., 2017; Nigam et al., 2015) . This could result in DDI interactions in renal impairment even when no interaction is expected based on the xenobiotics administered. It is critical to analyse the impact of these factors, along with renal function to elucidate the impact of renal impairment on the PK of drugs.
This simulation based study focused on a specific compound, γ-hydroxybutyric acid, which is representative of an actively reabsorbed compound in the kidney. We utilized a novel PK model with a renal clearance component that incorporates active reabsorption with vectorial proximal tubule transport and reabsorption of fluid along the nephron, an important model addition that modulates the concentration of drugs in the proximal tubule (Dave & Morris, 2015) . In this As expected, when renal function was decreased, there was an accompanying decrease in CL R (Figure 3 ). This effect was greater with increasing doses due to the dose-dependent kinetics of GHB. The dose dependent differences can be explained through the changes in overall CL. Overall CL decreases the least for the 200 mg/kg dose.
The greater impact of GFR reduction on CL for the higher doses is present because with an actively reabsorbed compound, CL R becomes a more significant contributor to CL as dose increases and saturation of reabsorption is present; therefore, the impact of renal impairment may be greater for the higher doses.
DT expression was shown to play a role in the PK of GHB in the presence of renal impairment. When DT expression was decreased 2-fold, there was an accompanying 1.5-fold increase in CL R when renal function was unchanged (Table 3) . Sodium/glucose transporter 2 (SGLT2) mRNA expression has been shown to decrease over 7-fold in 5/6 nephrectomized rats (Nakamura et al., 2004 ). This was accompanied by a 2.3 fold reduction in V max for glucose transport in brush border membrane vesicles isolated from nephrectomized rats (Nakamura et al., 2004) . The changes in the capacity of SGLT2 glucose transport in nephrectomized rats, likely mediated by a reduction in expression as the mRNA and V max data suggest, resulted in a 2.4-fold increase in CL R for glucose based on glucose/creatinine ratios (Nakamura et al., 2004) . Therefore, decreases in DTs involved in renal reabsorption might be expected in renal impairment, resulting in increases in CL R , as observed from our simulations with GHB.
In order to investigate the potential impact of accumulated uremic toxins, the impact of inhibition on γ-hydroxybutyric acid PK in the presence of renal impairment was also included in this analysis. The effects of inhibition were augmented when transporter expression was increased (Figure 4b,c) , and diminished when expression was decreased (Figure 4d ,e). The CL R for GHB was maximal with the maximal degree of inhibition, but was still dependent on renal function.
Experimentally, CL R was observed to increase in rats from 0.95 to 2.1 and 2.2 ml/min when a non-competitive MCT1 inhibitor AR-C155858 was administered 5 min after γ-hydroxybutyric acid at a dose of 1 or 5 mg/kg i.v., respectively (Vijay, Morse, & Morris, 2015) . Based on the plasma concentrations of AR-C155858 after doses of 1 and 5 mg/kg i.v. (Vijay et al., 2015) and its K i of 2.3 nM, the R value ([I]/K i ) would be 417 for the first hour after i.v. administration and over 4 for the next 300 min. The observed change in CL R of GHB in the presence of AR-C155858 is consistent with our simulations, which show an increase in CL R from 1.03 to 1.5, 2.1, and 2.2 ml/min for R values of 1, 10 and 100, respectively. Competitive inhibition also led to an increase in CL R but the values of CL R achieved were higher for non-competitive inhibition than for competitive inhibition, although the majority of the CL R values were within 2-fold of each other. The similar impact on CL R for both types of inhibition in renal impairment suggests that the type of inhibition is not as critical to PK predictions as the potency and concentration of the inhibitors. Changes in GFR had a significant impact on CL R in the presence of inhibition. For a single value of GFR, increasing the degree of inhibition (R), led to an increase in CL R (Table 3 and   S1 ). Therefore, the expected decrease in GFR and presence of DDI due to uremic toxins may result in opposing effects on CL R for actively reabsorbed compounds.
In the case of administering a transporter inhibitor to enhance the CL R of an actively reabsorbed compound, a proposed treatment option for γ-hydroxybutyric acid overdose, a decrease in GFR would lead to lower CL R values than expected with normal renal function.
Therefore, inhibition of renal reabsorption would represent a less effective treatment option for renally impaired patients. This has been observed with SGLT2 inhibitors for the treatment of Type 2 diabetes mellitus (T2DM). SGLT2 is responsible for 90% of glucose reabsorption in the kidney, inhibition of this reabsorption leads to an increase in glucose CL R , reducing hyperglycemia in T2DM
patients (Scheen, 2015) . The efficacy of several of these compounds, including dapagliflozin, was reported to decrease with increasing degrees of renal impairment, resulting in a reduction in glucose CL R , compared with patients without renal impairment (Scheen, 2015) . A single 50 mg dose of dapagliflozin resulted in a reduction in steady state glucose CL R to 58% and 16% for mild and severe renal impairment, respectively, when compared with glucose CL R in healthy patients (Kasichayanula et al., 2013) . Our simulations were consistent with what was observed with dapagliflozin;
non-competitive inhibition (R of 100) resulted in an increase in GHB CL R for all values of GFR compared with simulations without inhibition. However, when the GHB CL R was compared across different degrees of renal function, while keeping inhibition consistent (R of 100), CL R was reduced to 50% and 9% for 50% and 10% renal function, respectively, when compared with simulations with 100% renal function.
Similar trends were observed with fraction unbound: maximal CL R was achieved with a f u of 1 and 100% GFR. In renal impairment, we expect an increase in f u and a decrease in GFR. When f u was increased, there was an increase in CL R , while a decrease in GFR leads to a decrease in CL R . Due to the opposing effects of f u and GFR on CL R , it is possible that CL R could remain unchanged in renal impairment for some compounds. It is also possible that there could also be an increase in CL R for compounds that normally have a high degree FIGURE 7 3D mesh plot illustrating the effects of renal function (100%-10%) on renal clearance (CL R ) and overall clearance (CL) of γ-hydroxybutyric acid (1500 mg/kg single i.v. bolus dose), when expression of DMEs is altered (V MAX, MET parameter was perturbed ±1.5, 2, and 5-fold) of protein binding and undergo a significant increase in f u in renal impairment.
The magnitude of the impact of f u on CL was influenced by the contribution of CL R to total CL. At higher levels of DT expression, CL R was a smaller component of CL and the f e was smaller, due to an increased capacity for reabsorption. Therefore, the changes in CL as a result of changes in f u were decreased. When DT expression was decreased, the capacity for reabsorption was also decreased and CL R became a more significant contributor to CL. In this case, the impact of f u on CL R had a larger effect on CL. This suggests that the impact of changes in CL R that result from the physiological changes in renal impairment will be dependent on the magnitude of the contribution of CL R to CL.
The impact of altered drug metabolizing enzyme expression on CL R was minimal, but may play a significant role in the overall clearance of compounds such as γ-hydroxybutyric acid, which exhibits capacity-limited metabolism. When renal function was reduced to 50% which is consistent with values for chronic kidney disease, reduction in the expression of DMEs from 1.5-to 5-fold resulted in a 46%-81% reduction in overall CL. This is consistent with reduction in non-renal CL reported by Nolin et al. (2008) for subjects with CKD of 30%-67%. Although definitive comparisons are difficult to make due to the limited quantitative data on DME expression with RI, there is agreement between our simulated values and the literature reports. As expected, alterations in the expression of DMEs had a very minimal effect on CL R , since these represent independent clearance mechanisms.
There are some limitations to the model simulations performed in this study. There is the potential for changes in the fluid reabsorption along the nephron segments in chronic kidney disease. monocarboxylate transporter (Slc5a8) and the MCT family in the mouse kidney. 
